EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study
Evaluation of a Human 3D Airway Tissue Culture Model for the Study of Respiratory Syncytial Virus Infection and the Development of Antiviral Drugs
EDP-938, a Novel Nucleoprotein Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities In Vitro and in a Nonhuman Primate Model
EDP-938, a Novel RSV N-inhibitor, Administered Once or Twice Daily was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus (RSV)
EDP-938, a Novel, Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus: Preliminary Results of a Phase 1 Study in Healthy Subjects
EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV, Displays a High Barrier to Resistance In Vitro